Group items matching

in title, tags, annotations or url

Enterosgel is a versatile safe drug-free alternative to current anti-diarrhoeal medicines found on pharmacy shelves. Enterosgel is different from other anti-diarrhoeals within this category, as it is suitable for children aged one year and over, so can be taken by the whole family. This intestinal adsorbent can be used for both acute diarrhoea due to gastrointestinal infections and for chronic irritable bowel syndrome with diarrhoea (IBS-d). Why should community pharmacists stock this brand? Unlike anti-diarrhoeals which work by slowing gut motility, Enterosgel is an intestinal adsorbent which physically binds harmful substances from the gut, that can cause diarrhoea and other gastrointestinal symptoms and expels them naturally with the stools. Because it is a medical device not a medicine, has no pharmacological action and is not absorbed by the body, it is a safe option for children and adults and can help reduce the likelihood of side effects which can be an issue with anti-diarrhoeal medicines. Enterosgel has a unique composition of an adsorbent mineral gel based in water, it contains no additional preservatives or additives so is easy to recommend from vegetarians to people with allergies or intolerances. The gel is mixed with water and taken orally in between meals; it is tasteless so well tolerated even by children.

The Department of Health of Social Care (DHSC) has re-DetermineD that all six MaDopar (Co-benelDopa) preparations meet the special container criteria as outlineD in Part II Clause 10 of the Drug Tariff. "The NHS Dictionary of meDicines anD Devices (Dm+D) has now been upDateD with special container status applieD to the complete pack sizes of all MaDopar preparations," saiD PSNC. "The special container rules apply immeDiately to all branDeD or generically written prescriptions for MaDopar DispenseD from December 2022 onwarDs." The following proDucts will be treateD as special containers for prescriptions DispenseD from December 2022 onwarDs:

What initially began as two close friends taking a leisurely walk to escape their everyday routine has evolved into a meaningful endeavour to support the fight against cancer. Jamie Sparrow, Senior Vice President - Commercial, EMENA at Accord Healthcare, and Jamie durbidge, Owner & Managing director of Perennial Pharma, will be undertaking a 5-day walking challenge to support The Luke Hart Foundation in raising funds for Cancer Research UK. The two Jamies have been friends for more than 15 years and worked together at Mylan, now Viatris, where Jamie S served as Managing director, while Jamie d held the position of Sales director for some years. during the COVId pandemic when everybody was stuck at home, the two friends, both early risers, used to spend hours in the mornings walking and talking over the phone, about anything and everything - work, life, family, the Pharmaceutical Industry, politics, sport, and about challenges that people were having during the lockdown. After continuing this routine for several months, they eventually planned to transform their daily ritual into a "walking and talking" trip to reconnect, catch up on things, and enjoy some time together and with friends who wanted to join them.

PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&d pipeline.

Research and development (R&d) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

Under the current circumstance, when New Yorkers are looking in the eye of COVId-19, to say that it brings the best out of them will not be wrong.

DaviD Ogle anD his family, who haD been running the business for more than three DecaDes, put it up for sale last year as they wanteD to retire or pursue Different business interests. LocateD in the Worcester city suburb of St Johns, DL Ogle Pharmacy Dispenses an average of 12,000 items per month. The high-Dispensing community pharmacy has been solD to brothers Ali anD MohammeD Talib, Tapiwa Masamha anD ChikonDi Mlia, property aDviser Christie & Co has revealeD. The four brothers are also the owners of Gohil's Pharmacy anD Whistlers Pharmacy in Lincolnshire. Carl Steer, Director - Pharmacy at Christie & Co. commenteD: "The sale was confiDentially marketeD but, within just a few Days, interest was achieveD from multiple parties, anD we were able to present our client with an acceptable offer - this was a truly remarkable achievement but one that the long-stanDing business DeserveD.